Clinical Trials Logo

Acute Myeloid Leukemia clinical trials

View clinical trials related to Acute Myeloid Leukemia.

Filter by:

NCT ID: NCT04614636 Terminated - Multiple Myeloma Clinical Trials

FT538 in Subjects With Advanced Hematologic Malignancies

Start date: October 17, 2020
Phase: Phase 1
Study type: Interventional

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

NCT ID: NCT04613622 Recruiting - Clinical trials for Acute Myeloid Leukemia

Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia

Start date: August 1, 2020
Phase:
Study type: Observational

Venetoclax is a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, the pharmacokinetic data in Chinese population, as well as the change of venetoclax plasma concentration while taking CYP enzyme inducers or inhibitors, remained unknown so far. Therefore, the aim of this study is to investigate the pharmacokinetic characteristics of venetoclax.

NCT ID: NCT04609826 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

DHODH
Start date: November 26, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.

NCT ID: NCT04599543 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia

Start date: November 15, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia.

NCT ID: NCT04589728 Recruiting - Clinical trials for Acute Myeloid Leukemia

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Start date: February 23, 2021
Phase:
Study type: Observational

This is an retrospective and prospective observational multinstitutional study to evaluate the impact on outcome of the combination of HMA plus venetoclax in AML patients unfit for intensive chemotherapy in a "real-life" scenario. No additional procedures or visits other than those required by normal clinical practice will be required. Patients will be observed for at least 24 months.

NCT ID: NCT04581512 Recruiting - Clinical trials for Acute Myeloid Leukemia

Study to Evaluate the Safety and Tolerability of EP0042

Start date: November 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

NCT ID: NCT04580121 Completed - Clinical trials for Acute Myeloid Leukemia

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Start date: November 4, 2020
Phase: Phase 1
Study type: Interventional

This open-label, entry-into-human (EIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of RO7283420. Escalating doses of RO7283420 will be administered to participants with Acute Myeloid Leukemia (AML) in order to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

NCT ID: NCT04571645 Terminated - Clinical trials for Acute Myeloid Leukemia

Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

AML
Start date: April 30, 2021
Phase: Phase 3
Study type: Interventional

Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.

NCT ID: NCT04570709 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

RN-Led Palliative and Supportive Care Intervention

Start date: September 14, 2020
Phase: N/A
Study type: Interventional

This single institution feasibility and acceptability study includes patients with acute leukemia which is designed to examine a novel palliative and supportive care intervention (Palliative and supportive Care inTervention; PACT) in which registered nurses (RNs), occupational therapists (OTs), and physical therapists (PTs) address the activity needs of older adults with acute leukemia during their hospital stay.

NCT ID: NCT04553692 Recruiting - Colorectal Cancer Clinical Trials

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Start date: September 23, 2020
Phase: Phase 1
Study type: Interventional

This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of aplitabart+FOLFIRI+bevacizumab.